Hamden’s RxGen is sharing its research models into eye ailments that affect monkeys with a French research firm that does similar preclinical research leading to treatments for human sight.
RxGen and Iris Pharma, of Nice, France, didn’t reveal financial terms of their research-sharing alliance.
Both say they aim to offer “bench-to-bedside” ophthalmology research services to the pharmaceutical and biotechnology industries worldwide.
RxGen’s expertise is researching and modeling what potential treatments will work – or not – using live primates.
Iris Pharma, in turn, will leverage RxGen’s models with its own research on human eye ailments to shorten the preclinical and clinical development time in bringing effective eye treatments to market, authorities said.
“Effectively translating discovery to approved therapeutic demands time and cost efficient program design and management, capitalizing on the best available preclinical test systems while maintaining a clear eye on the clinical pathway”, RxGen CEO Matthew Lawrence said in a statement.
